Skip to main content
Clinical Trials/NCT06113965
NCT06113965
Withdrawn
Not Applicable

Neural Operant Conditioning to Improve Walking After Stroke

MetroHealth Medical Center1 site in 1 country60 target enrollmentDecember 31, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Stroke
Sponsor
MetroHealth Medical Center
Enrollment
60
Locations
1
Primary Endpoint
Surface electromyographic recording of leg muscles
Status
Withdrawn
Last Updated
last year

Overview

Brief Summary

The goal of this clinical trial is to learn if operant conditioning can reduce spasticity in order to improve walking in stroke patient. The main questions it aims to answer are:

  • Can participants self-regulate reflex excitability
  • Can participants self-regulate reflex, reduce spasticity and improve walking Participants will undergo surface stimulation to evoke spinal reflexes and will be asked to control these reflexes therefore reducing spasticity.

Researchers will compare result to able bodied participants to see if [insert effects]

Detailed Description

The study purpose is to investigate the possibility and later effect of spinal reflex self-regulation in post-stroke stiff-knee gait. The intervention will consist of direct current surface stimulation of the peripheral nerves using electrical stimulation. Stimulation will evoke a motor response that will be collected through surface EMG electrodes and processed to depict a measure of the response as feedback to the participant to complete the loop of operant conditioning. The participant will attempt to modulate their responses over multiple sessions to cause this depiction to either increase or decrease its value depending on an established target. .

Registry
clinicaltrials.gov
Start Date
December 31, 2024
End Date
May 31, 2028
Last Updated
last year
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

James Sulzer

James Sulzer, PhD

MetroHealth Medical Center

Eligibility Criteria

Inclusion Criteria

  • Sign and date consent form
  • At least 3 months since stroke event
  • Over 18 years of age at time of eligibility
  • Ability to stand upright and walk for at least 5 minutes
  • Premorbidly independent
  • Mild to moderate gait impairment
  • Reduced knee flexion during walking relative to the unimpaired side
  • Unilateral hemiparesis of the lower limbs
  • Ability to evoke muscle responses through peripheral nerve stimulation, spinal cord stimulation, and transcranial magnetic stimulation
  • Medically stable

Exclusion Criteria

  • Co-existing neurological condition other than prior stroke involving the hemiparetic lower limb (e.g., peripheral nerve injury, PD, SCI, TBI, MS).
  • History of lower limb musculoskeletal injury
  • Functionally relevant osteoarthritis and weight bearing restriction
  • Functionally relevant polyneuropathy resulting in lack of sensation in the lower leg
  • Functionally relevant cognitive impairment
  • Functionally relevant vision impairment
  • Botox injection to the ipsilateral leg in the last 12 weeks or taking oral anti-spasticity medications
  • Taking part in physical therapy for any walking-related impairment
  • Cardiac pacemaker or other implanted electronic systems
  • Uncontrolled seizure disorder

Outcomes

Primary Outcomes

Surface electromyographic recording of leg muscles

Time Frame: baseline, week 6 -mid-treatment, week 12 - end of treatment, 4-week post treatment, 12 weeks post treatment, 24 weeks post treatment

Recording electrical activity of leg muscles during walking in response to peripheral nerve stimulation

Secondary Outcomes

  • 10 meter walk test(baseline, week 6 -mid-treatment, week 12 - end of treatment, 4-week post treatment, 12 weeks post treatment, 24 weeks post treatment)
  • quadriceps pendulum test(baseline, week 6 -mid-treatment, week 12 - end of treatment, 4-week post treatment, 12 weeks post treatment, 24 weeks post treatment)
  • Five Times Sit to Stand Test(baseline, week 6 -mid-treatment, week 12 - end of treatment, 4-week post treatment, 12 weeks post treatment, 24 weeks post treatment)
  • Transcranial Magnetic Stimulation (TMS)(Baseline, Week 12 - end of treatment)

Study Sites (1)

Loading locations...

Similar Trials